Addressing Inflammation and Role of Colchicine in ASCVD, with Michael J. Blaha, MD, MPH

Michael J. Blaha, MD, MPH, discusses his interpretation of the growing data detailing the role of inflammation as a driver of cardiovascular risk and how clinicians can identify patients who stand to benefit most from colchicine 0.5 mg tablets.

Related Keywords

Paul Ridker ,Michaelj Blaha ,Novartis Corporation ,Amgen ,Ciccarone Center ,Bayer Healthcare Pharmaceuticals ,Drug Administration ,American College Of Cardiology ,Novo Nordisk ,Clinical Research ,American College ,Cardiovascular Disease Prevention ,Heart Disease ,Johns Hopkins ,Colchicine ,Slodoco ,Colchicine Lodoco ,Michael Blaha ,Agepha Pharma ,Ascvd ,Inflammation And Ascvd ,Ascvd And Inflammation ,